Literature DB >> 28768909

Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI.

Yue Zhang1, Durga Udayakumar1,2, Ling Cai3,4, Zeping Hu3, Payal Kapur5,6,7, Eun-Young Kho3, Andrea Pavía-Jiménez7,8, Michael Fulkerson1, Alberto Diaz de Leon1, Qing Yuan1, Ivan E Dimitrov2,9, Takeshi Yokoo1,2, Jin Ye10, Matthew A Mitsche10, Hyeonwoo Kim10, Jeffrey G McDonald10, Yin Xi1, Ananth J Madhuranthakam1,2, Durgesh K Dwivedi1, Robert E Lenkinski1,2, Jeffrey A Cadeddu1,6, Vitaly Margulis6, James Brugarolas7,8, Ralph J DeBerardinis3, Ivan Pedrosa1,2,7.   

Abstract

BACKGROUND: Dysregulated lipid and glucose metabolism in clear cell renal cell carcinoma (ccRCC) has been implicated in disease progression, and whole tumor tissue-based assessment of these changes is challenged by the tumor heterogeneity. We studied a noninvasive quantitative MRI method that predicts metabolic alterations in the whole tumor.
METHODS: We applied Dixon-based MRI for in vivo quantification of lipid accumulation (fat fraction [FF]) in targeted regions of interest of 45 primary ccRCCs and correlated these MRI measures to mass spectrometry-based lipidomics and metabolomics of anatomically colocalized tissue samples isolated from the same tumor after surgery.
RESULTS: In vivo tumor FF showed statistically significant (P < 0.0001) positive correlation with histologic fat content (Spearman correlation coefficient, ρ = 0.79), spectrometric triglycerides (ρ = 0.56) and cholesterol (ρ = 0.47); it showed negative correlation with free fatty acids (ρ = -0.44) and phospholipids (ρ = -0.65). We observed both inter- and intratumoral heterogeneity in lipid accumulation within the same tumor grade, whereas most aggressive tumors (International Society of Urological Pathology [ISUP] grade 4) exhibited reduced lipid accumulation. Cellular metabolites in tumors were altered compared with adjacent renal parenchyma.
CONCLUSION: Our results support the use of noninvasive quantitative Dixon-based MRI as a biomarker of reprogrammed lipid metabolism in ccRCC, which may serve as a predictor of tumor aggressiveness before surgical intervention. FUNDING: NIH R01CA154475 (YZ, MF, PK, IP), NIH P50CA196516 (IP, JB, RJD, JAC, PK), Welch Foundation I-1832 (JY), and NIH P01HL020948 (JGM).

Entities:  

Keywords:  Metabolism; Oncology

Year:  2017        PMID: 28768909      PMCID: PMC5543910          DOI: 10.1172/jci.insight.94278

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  55 in total

1.  Renal epithelial neoplasms: the diagnostic implications of electron microscopic study in 55 cases.

Authors:  Bhuvaneswari Krishnan; Luan D Truong
Journal:  Hum Pathol       Date:  2002-01       Impact factor: 3.466

Review 2.  Tumor-induced alterations in lipid metabolism.

Authors:  M Notarnicola; V Tutino; M G Caruso
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

3.  A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.

Authors:  Ilkay S Idilman; Onur Keskin; Azim Celik; Berna Savas; Atilla Halil Elhan; Ramazan Idilman; Musturay Karcaaltincaba
Journal:  Acta Radiol       Date:  2015-04-08       Impact factor: 1.990

4.  Use of patient-specific MRI-based prostate mold for validation of multiparametric MRI in localization of prostate cancer.

Authors:  Hari Trivedi; Baris Turkbey; Ardeshir R Rastinehad; Compton J Benjamin; Marcelino Bernardo; Thomas Pohida; Vijay Shah; Maria J Merino; Bradford J Wood; W Marston Linehan; Aradhana M Venkatesan; Peter L Choyke; Peter A Pinto
Journal:  Urology       Date:  2012-01       Impact factor: 2.649

Review 5.  Fatty acid synthase and cancer: new application of an old pathway.

Authors:  Francis P Kuhajda
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

Review 6.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

7.  Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O.

Authors:  J L Ramírez-Zacarías; F Castro-Muñozledo; W Kuri-Harcuch
Journal:  Histochemistry       Date:  1992-07

8.  Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma.

Authors:  Patrick E Teloken; R Houston Thompson; Satish K Tickoo; Angel Cronin; Caroline Savage; Victor E Reuter; Paul Russo
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

9.  Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma.

Authors:  Akio Horiguchi; Tomohiko Asano; Takako Asano; Keiichi Ito; Makoto Sumitomo; Masamichi Hayakawa
Journal:  J Urol       Date:  2008-07-18       Impact factor: 7.450

10.  Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma.

Authors:  Giuseppe Lucarelli; Vanessa Galleggiante; Monica Rutigliano; Francesca Sanguedolce; Simona Cagiano; Pantaleo Bufo; Gaetano Lastilla; Eugenio Maiorano; Domenico Ribatti; Andrea Giglio; Grazia Serino; Antonio Vavallo; Carlo Bettocchi; Francesco Paolo Selvaggi; Michele Battaglia; Pasquale Ditonno
Journal:  Oncotarget       Date:  2015-05-30
View more
  15 in total

Review 1.  Applications of metabolomics to study cancer metabolism.

Authors:  Akash K Kaushik; Ralph J DeBerardinis
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-04-25       Impact factor: 10.680

Review 2.  Mechanisms and Implications of Metabolic Heterogeneity in Cancer.

Authors:  Jiyeon Kim; Ralph J DeBerardinis
Journal:  Cell Metab       Date:  2019-09-03       Impact factor: 27.287

Review 3.  Radiomics in Kidney Cancer: MR Imaging.

Authors:  Alberto Diaz de Leon; Payal Kapur; Ivan Pedrosa
Journal:  Magn Reson Imaging Clin N Am       Date:  2019-02       Impact factor: 2.266

4.  Renal and adrenal masses containing fat at MRI: Proposed nomenclature by the society of abdominal radiology disease-focused panel on renal cell carcinoma.

Authors:  Nicola Schieda; Matthew S Davenport; Ivan Pedrosa; Atul Shinagare; Hersch Chandarana; Nicole Curci; Ankur Doshi; Gary Israel; Erick Remer; Jane Wang; Stuart G Silverman
Journal:  J Magn Reson Imaging       Date:  2019-01-28       Impact factor: 4.813

Review 5.  SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond.

Authors:  Russell A DeBose-Boyd; Jin Ye
Journal:  Trends Biochem Sci       Date:  2018-02-27       Impact factor: 13.807

6.  Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma.

Authors:  JungYeon Kim; Bonne Thompson; Sungwon Han; Yair Lotan; Jeffrey G McDonald; Jin Ye
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2019-09-09       Impact factor: 4.698

Review 7.  Imaging of Solid Renal Masses.

Authors:  Fernando U Kay; Ivan Pedrosa
Journal:  Urol Clin North Am       Date:  2018-06-15       Impact factor: 2.241

8.  Pivotal biomarker expression and drug screening in advanced ccRCC.

Authors:  Wen Xiao; Ke Chen; Xiaoping Zhang
Journal:  Clin Transl Med       Date:  2020-06-21

9.  Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo.

Authors:  Kevin D Courtney; Divya Bezwada; Tomoyuki Mashimo; Kumar Pichumani; Vamsidhara Vemireddy; Alexander M Funk; Jennifer Wimberly; Sarah S McNeil; Payal Kapur; Yair Lotan; Vitaly Margulis; Jeffrey A Cadeddu; Ivan Pedrosa; Ralph J DeBerardinis; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher
Journal:  Cell Metab       Date:  2018-08-23       Impact factor: 27.287

Review 10.  Fibroblasts as Modulators of Local and Systemic Cancer Metabolism.

Authors:  Hannah Sanford-Crane; Jaime Abrego; Mara H Sherman
Journal:  Cancers (Basel)       Date:  2019-05-03       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.